CD4 and neoplasm: These trials provide a rationale for the development of this approach in patients whose tumours have a high mutation frequency, particularly in combination with checkpoint blockade, and highlight the importance of CD4 T-cell recognition of tumours in combination with CD8 T-cell responses.